iBio, Inc. Files 8-K with Regulatory Disclosures

Ticker: IBIO · Form: 8-K · Filed: 2025-06-24T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, regulatory-disclosure, financials

TL;DR

iBio filed an 8-K on 6/24/25 covering Reg FD, other events, and financials.

AI Summary

On June 24, 2025, iBio, Inc. filed an 8-K report detailing several events. The company announced a Regulation FD Disclosure, indicating a public disclosure of material information. Additionally, the filing includes "Other Events" and "Financial Statements and Exhibits," suggesting updates on corporate activities and financial reporting.

Why It Matters

This 8-K filing signals important updates from iBio, Inc. to the public, potentially affecting investors' understanding of the company's current status and future outlook.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant information, but without specific details on the 'Other Events' or the nature of the Regulation FD disclosure, the immediate risk impact is uncertain.

Key Numbers

Key Players & Entities

FAQ

What specific information was disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure but does not specify the exact information released in this section.

What are the 'Other Events' mentioned in the filing?

The filing lists 'Other Events' as an item but does not provide details on what these events entail.

What is the purpose of including 'Financial Statements and Exhibits' in this 8-K?

This suggests that the filing includes updated financial information or exhibits relevant to the reported period or events.

When was iBio, Inc. incorporated?

iBio, Inc. was incorporated in Delaware.

What is the principal executive office address for iBio, Inc.?

The principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.

From the Filing

0001420720-25-000029.txt : 20250624 0001420720-25-000029.hdr.sgml : 20250624 20250624075651 ACCESSION NUMBER: 0001420720-25-000029 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20250624 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250624 DATE AS OF CHANGE: 20250624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 251066702 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20250624x8k.htm 8-K iBio, Inc._June 24, 2025 0001420720 false 0001420720 2025-06-24 2025-06-24 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 24, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 11750 Sorrento Valley Road, Suite 200 San Diego , California 92121 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock , $0.001 par value per share IBIO The Nasdaq Stock Market LLC ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ​ ​ ​ ​ Item 7.01. Regulation FD Disclosure. ​ iBio, Inc. (the “Company”) has updated its corporate presentation. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K. ​ The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicatin

View on Read The Filing